Robert Aubrey is Managing Director of IR2Dx Canada and Vice President, Business Development. Mr. Aubrey joined IR2Dx in July 2010, when he incorporated our research affiliate in Canada with headquarters in Edmonton, Alberta. He has extensive experience in medical products, biotechnology and diagnostics, particularly in oncology. He worked at Abbott Laboratories for over 12 years, and demonstrated success in the Cancer Business Unit, where his responsibility included worldwide marketing and support for CEA testing. He spent over 16 years at Biomira, where he drove the first pharmaceutical-like prospective randomized trial for a diagnostic. The trial demonstrated that Biomira’s breast cancer marker was the first cancer antigen providing a minimum of 10 months advance warning of recurrent disease in previously treated stage II/III women in remission following curative adjuvant treatment. Mr. Aubrey led the licensing of this test to several fully automated diagnostic companies, and it became the market leading antigen in the US following its PMA approval by the FDA in 1996. Mr. Aubrey sold this business to Centocor in 1998. As Vice President of Business Development, he has led negotiations with Merck KGaA, licensing two late stage cancer vaccines to the German partner for $33 Million in up-front license and equity fees, to a total value in excess of $160 million, not counting sales milestones and a 50/50 co-promotion arrangement in the U.S. At the time (2001), this was the largest worldwide alliance in cancer vaccines. Additionally, Mr. Aubrey has negotiated numerous other license agreements for Biomira, now Oncothyreon. He has broad experience in selling, managing a sales force, international diagnostic marketing, and introducing novel cancer diagnostics to the market.